Issue 7, 2014

Modern multicomponent reactions for better drug syntheses

Abstract

Multicomponent reaction (MCR) technology is now widely recognized for its impact on drug discovery projects and is strongly endorsed by industry as well as academia. However, still relatively few products based on MCRs are marketed or under development. This provides tremendous opportunities for organic chemists to shorten synthetic pathways, thus reducing the cost-of-goods considerably. A recent example of the HCV drug Telaprevir is highlighted where introduction of two MCRs could lead to a shortening of the synthesis route by more than 50%.

Graphical abstract: Modern multicomponent reactions for better drug syntheses

Article information

Article type
Highlight
Submitted
24 mar 2014
Accepted
12 jun 2014
First published
18 jun 2014
This article is Open Access
Creative Commons BY license

Org. Chem. Front., 2014,1, 834-837

Modern multicomponent reactions for better drug syntheses

T. Zarganes-Tzitzikas and A. Dömling, Org. Chem. Front., 2014, 1, 834 DOI: 10.1039/C4QO00088A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements